Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is caused by contraction of the D4Z4 repeat array. Recent studies revealed that the \textit{FAT1} expression is associated with disease activity of FSHD, and the \textit{FAT1} alterations result in myopathy with a FSHD-like phenotype. We describe a 59-year-old woman with both contracted D4Z4 repeat units and a \textit{FAT1} mutation. Shoulder girdle muscle weakness developed at the age of 56 years, and was followed by proximal leg weakness. When we examined her at 59 years of age, she displayed asymmetric and predominant weakness of facial and proximal muscles. Muscle biopsy showed increased variation in fiber size and multifocal degenerating fibers with lymphocytic infiltration. Southern blot analysis revealed 8 D4Z4 repeat units, and targeted sequencing of modifier genes demonstrated the c.10331 A>G variant in the \textit{FAT1} gene. This \textit{FAT1} variant has previously been reported as pathogenic variant in a patient with FSHD-like phenotype. Our study is the first report of a \textit{FAT1} mutation in a FSHD1 patient, and suggests that \textit{FAT1} alterations might work as a genetic modifier.

**Key Words:** Facioscapulohumeral muscular dystrophies, muscular dystrophy, \textit{FAT1}

**INTRODUCTION**

Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a common muscular dystrophy characterized by an asymmetric descending progression starting in the face or shoulder-girdle muscles. FSHD1 is caused by contraction of the D4Z4 repeat array on chromosome 4q35 to a size of 1 to 10 units. The clinical severity of FSHD1 is inversely correlated with D4Z4 repeat units, and many patients with 7 to 10 D4Z4 repeat units have mild disease activity and remain nonpenetrant.\(^1,2\) Additionally, the D4Z4 repeat of 8–10 units is found in 1–3% of the healthy control populations.\(^3\) However, the repeat units are not always predictive for clinical severity, and patients with 8 to 10 D4Z4 repeat units occasionally revealed early symptom onset and severe clinical phenotype.\(^1\) Actually, the \textit{SMCHD1} and \textit{DNMT3B} genes have recently been identified as genetic modifiers in FSHD1.\(^4,5\)

The \textit{FAT1} gene is located on chromosome 4q35 proximal to the D4Z4 repeat array. The \textit{FAT1} mutations are linked to various diseases including schizophrenia, bipolar disorder, and cancer. It is known that this gene influences muscle patterning, regionalized muscle wasting, and adult muscle fiber functions.\(^6\) Furthermore, faulty regulation of the \textit{FAT1} expression was observed in FSHD1 muscle tissue, and mutations in \textit{FAT1} were found in patients with a FSHD-like phenotype.\(^7,8\)

To identify the existence of a genetic modifier in Korean patients with FSHD1, we performed targeted sequencing of \textit{SMCHD1}, \textit{DNMT3B}, and \textit{FAT1} genes in patients with 8–10 D4Z4 repeat units. Then, we found that one patient had both 8 D4Z4 repeat units and a \textit{FAT1} mutation.
CASE REPORT

A 59-year-old woman in the MF1147 family presented to our neurologic clinic with proximal muscle weakness. She did not have a family history of any neuromuscular disorders. She first had gait disturbance and low back pain since her twenties. She felt weakness in shoulder girdle muscles at the age of 56 years. Then, she had had difficulty to rise from the floor since the age of 57 years. When we examined her at 59 years, she could walk independently. She displayed asymmetric and predominant weakness of shoulder and hip girdle muscles. Additionally, she had facial muscle weakness. She did not exhibit sensory deficits and joint contractures. Her serum creatine kinase level was 140 IU/L (reference value: <135 IU/L). Needle electromyography was compatible with generalized myopathy. A biceps brachii muscle biopsy was performed.

Fig. 1. Histopathological results and T1-weighted MR images of whole body. (A) Hematoxylin and eosin (H-E) staining revealed increased variation in fiber size and multifocal degenerating fibers with lymphocytic infiltration. (B) Modified Gomori-trichrome (GT) staining did not reveal any intracytoplasmic inclusions and subsarcolemmal depositions. (C) Staining with reduced nicotinamide adenine dinucleotide-tetrazolium reductase (NADH-tr) showed mild disorganization of intermyofibrillar network. (A, H-E stain, ×200; B, modified GT stain, x100; and C, NADH-tr stain, ×100). (D-G) T1-weighted MR images of whole body. (D) At the upper arm level, biceps brachii muscles were shown to be predominantly affected on the right side (white arrows). (E) At the abdominal level, both abdominal (black arrow heads) and paraspinal (black arrows) muscles were found to be totally replaced by fat tissues. (F) At the thigh levels, semitendinosus, semimembranosus, biceps femoris, vastus medialis, and vastus intermedius muscles were totally replaced by the fat tissue. Rectus femoris muscles were shown to be severely affected on the right side (white arrow heads). (G) At the calf level, bilateral soleus muscles were shown to be predominantly affected.
(Fig. 1A-C). Hematoxylin and eosin staining revealed increased fiber size variability, increased endomysial fibrosis, and multifocal degenerating fibers with lymphocytic infiltration. Modified Goemori-trichrome staining did not demonstrate any intracytoplasmic inclusions and subsarcolemmal depositions. Staining with reduced nicotinamide adenine dinucleotide-tetrazodium reductase showed mild disorganization of intermyofibrillar network. Whole body MR images were performed (Fig. 1D-G). At the upper arm level, T1-weighted MR images demonstrated predominant fatty replacement of right biceps brachii muscle. At the abdominal level, both abdominal and paraspinal muscles were found to have been totally replaced by fat tissues. At the thigh levels, semitendinosus, semimembranosus, biceps femoris, vastus medialis, and vastus intermedius muscles were shown to be totally replaced by the fat tissue. Rectus femoris muscle on the right side was severely affected. At the calf level, the MR image revealed bilateral soleus muscles predominantly affected.

Based on these clinical, pathological, and radiological presentation, we assumed that her disease was FSHD1. To determine the size of the D4Z4 repeat arrays, we performed Southern blot analysis and found 8 D4Z4 repeat units, therefore, she was diagnosed with FSHD1. Subsequently, we performed targeted-next generation sequencing of modifier genes including the SMCHD1, DNMT3B, and FAT1 genes to find the existence of a genetic modifier in Korean patients with FSHD1. Targeted sequencing was performed in 9 unrelated patients. All patients had asymmetric descending progression starting in the face or shoulder-girdle muscles and carried a contracted allele from 8 to 10 D4Z4 repeat units. Finally, we identified previously reported c.10331 A>G (p.N3444S) variant in FAT1 gene in the present case. This FAT1 variant was previously reported as a mutation in a myopathy patient who had a FSHD-like phenotype but did not have the contraction of the D4Z4 repeat units.

**DISCUSSION**

In the present study, we identified a FAT1 mutation in a Korean patient with the shortening. The c.10331 A>G FAT1 variant has rarely been reported in dbSNP142 and the Exome Variant Server with allele frequencies of 0.00008. However, in vitro functional study demonstrated that this variant induced partial alteration of splicing by breaking an exonic splicing enhancer. Therefore, c.10331 A>G variant in the FAT1 gene is a pathogenic variant and influenced clinical phenotype of the present patient.

The FAT1 gene encodes a single pass transmembrane protein with the extracellular portion consisting of 34 cadherin repeats, five EGF-like domains and a laminin-G like domain. This protein belongs to the FAT cadherin superfamily and influences multiple biological activities, including smooth muscle cell motility, actin accumulation, cell polarity, and migrating muscle precursors. Recent studies demonstrated that the FAT1 expression is closely related with disease onset and the alterations in FAT1 gene cause FSHD-like myopathy. However, the pathogenic mechanism of FAT1 mutations in myopathy remains unclear.

The present case revealed facial diplegia, asymmetric descending progression, and lymphocytic infiltration. It was compatible with FSHD1, but we could not find any add-on effects of FAT1 alterations. It is probably because that the clinical presentation of FAT1 myopathy closely resembles that of FSHD1. Previous study demonstrated predominant involvement of facial, scapular, and humeral muscles and progression of the disease toward the lower limbs in patients with FAT1 mutations. These findings are typical clinical features of FSHD1. We initially planned neurological examination and segregation study of the D4Z4 contraction and the FAT1 mutation in the family. However, the patient and her family members refused further evaluation and genetic testing. Further studies are needed to identify the role of a genetic modifier of FAT1 gene in FSHD1.

In conclusion, our study is the first report of coexistence of the contracted D4Z4 repeats and FAT1 mutation in a FSHD1 patient.

**ACKNOWLEDGEMENTS**

This research was supported by Memorial Foundation for Dr. Suh Succ-jo by named Hyangseal, Korean Neurological Association Grant No. KNA-14-HS-01.

**ORCID**

Hyung Jun Park  https://orcid.org/0000-0003-4165-8901  
Wookjae Lee  https://orcid.org/0000-0001-8891-9035  
Young-Chul Choi  https://orcid.org/0000-0001-5525-6861

**REFERENCES**

1. Park HJ, Hong JM, Lee JH, Lee HS, Shin HY, Kim SM, et al. Low D4Z4 copy number and gender difference in Korean patients with facioscapulohumeral muscular dystrophy type 1. Neuromuscul Disord 2015;25:859-64.
2. Statland JM, Donlin-Smith CM, Tapscott SJ, Lemmers RJ, van der Maarel SM, Tawil R. Milder phenotype in facioscapulohumeral dystrophy with 7-10 residual D4Z4 repeats. Neurology 2015;85:2147-50.
3. Scionti I, Fabbri G, Fiorillo C, Ricci G, Greco F, D’Amico R, et al. Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic counselling. J Med Genet 2012;49:171-8.
4. Sacconi S, Lemmers RJ, Balog I, van der Vliet PJ, Lahaut P, van Nieuwenhuijen MP, et al. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1. Am J Hum Genet 2013;93:743-51.
5. van den Boogaard ML, Lemmers RJLF, Balog J, Wohlgemuth M,
Auranen M, Mitsushashi S, et al. Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy. Am J Hum Genet 2016;98:1020-9.
6. Caruso N, Herberth B, Bartoli M, Puppo F, Dumonceaux J, Zimmermann A, et al. Deregulation of the protocadherin gene FAT1 alters muscle shapes: implications for the pathogenesis of facioscapulohumeral dystrophy. PLoS Genet 2013;9:e1003550.
7. Mariot V, Roche S, Houdé C, Porilho D, Sacconi S, Puppo F, et al. Correlation between low FAT1 expression and early affected muscle in facioscapulohumeral muscular dystrophy. Ann Neurol 2015;78:387-400.
8. Puppo F, Dionnet E, Gaillard MC, Gaildrat P, Castro C, Vovan C, et al. Identification of variants in the 4q35 gene FAT1 in patients with a facioscapulohumeral dystrophy-like phenotype. Hum Mutat 2015;36:443-53.
9. Hou R, Sibinga NE. Atrophin proteins interact with the Fat1 cadherin and regulate migration and orientation in vascular smooth muscle cells. J Biol Chem 2009;284:6955-65.
10. Moeller MJ, Soofi A, Braun GS, Li X, Watzl C, Kriz W, et al. Protocadherin FAT1 binds Ena/VASP proteins and is necessary for actin dynamics and cell polarization. EMBO J 2004;23:3769-79.
11. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD. Delineation of a Fat tumor suppressor pathway. Nat Genet 2006;38:1142-50.
12. Skouloudaki K, Puetz M, Simons M, Courbard JR, Boehrke C, Hartleben B, et al. Scribble participates in Hippo signaling and is required for normal zebrafish pronephros development. Proc Natl Acad Sci U S A 2009;106:8579-84.